Diabetes mellitus: Subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 3, 2000, Pages 823-829

  Kuller, Lewis H ^a   Velentgas, Priscilla ^b   Barzilay, Joshua ^c   Beauchamp, Norman J ^d   O'Leary, Daniel H ^e   Savage, Peter J ^f  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b CHS Coordinating Center   (United States)

^c KAISER PERMANENTE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Atherosclerosis; Diabetes; Heart attack; Stroke; Subclinical disease

Indexed keywords

GLUCOSE;

AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE;

EID: 0034016828     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.3.823     Document Type: Article

References (43)

1. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, ed. Diabetes in America. 2nd ed, Bethesda, Md: National Institutes of Health; 1995:429-448.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
3. Bierman EL. Atherogenesis in diabetes. Arterioscler Thromb. 1992;12: 647-656.
4. Aoki I, Shimoyama K, Aoki N, Homori M, Yanagisawa A, Nakahara K, Kawai Y, Kitamura SI, Ishikawa K. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. J Am Coll Cardiol. 1996;27:560-566.
5. Zhang J, Ren S, Sun D, Shen GX. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:1140-1148.
6. Kuller L, Fisher L, McClelland R, Fried L, Cushman M, Jackson S, Manolio T. Differences in prevalence of and risk factors for subclinical vascular disease among black and white participants in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1998;18:283-293.
7. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1997;20:935-942.
8. Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes RW, Cram KB, Hutchinson RG, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Stroke. 1994;25:66-73.
9. D'Agostino RB Jr, Mykkanen L, Goff DC, Marian R, Selby JV, Howard G, Haffner SM. Atherosclerosis in type 2 diabetic and non-diabetic subjects with and without previous myocardial infarction: the Insulin Resistance Atherosclerosis Study (IRAS). In: Abstracts of the 38th Annual Conference on Cardiovascular Disease Epidemiology and Prevention; March 18-20, 1998; Santa Fe, NM.
10. Kuller LH, Shemanski L, Psaty BM, Borhani NO, Gardin J, Haan MN, O'Leary DH, Savage PJ, Tell GS, Tracy R. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation. 1995;92: 720-726.
11. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D, for the CHS Collaborative Research Group. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:538-545.
12. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2898.
13. Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak JF, Bovill E, Gottdiener JS. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: The Cardiovascular Health Study. Arch Intern Med. 1999;159:1339-1347.
14. Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR, for the CHS Collaborative Research Group. Short-term predictors of incident stroke in older adults: the Cardiovascular Health Study. Stroke. 1996;27: 1479-1486.
15. Gottdiener JS, Shemanski L, Gardin JM, Aurigemma G, Kitzman DW. Echocardiographic predictors of incident congestive heart failure in elderly without prevalent cardiovascular disease: the Cardiovascular Health Study. Circulation. 1996;94(suppl I):I-691. Abstract.
16. Kuller L, Borhani N, Furberg C, Gardin J, Manolio T, O'Leary D, Psaty B, Robbins J. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol. 1994;139:1164-1179.
17. Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, Dobs A, Polak JF, Savage PJ. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet. 1999;354: 622-625.
18. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O'Leary DH, Psaty B, Rautaharju P, Tracy RP, Weiler PG for the CHS Research Group. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1:263-276.
19. Mittelmark BM, Psaty BM, Rautaharju PM, Fried LP, Borhani NO, Tracy RP, Gardin JM, O'Leary DH, for the Cardiovascular Health Study Collaborative Research Group. Prevalence of cardiovascular diseases among older adults: the Cardiovascular Health Study. Am J Epidemiol. 1993; 137:311-317.
20. Price TR, Psaty B, O'Leary D, Burke G, Gardin J, for the Cardiovascular Health Study Research Group. Assessment of cerebrovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:504-507.
21. DeBacquer D, DeBacker G, Kornitzer M, Blackburn H. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart. 1998;80:570-577.
22. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RF. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41:264-270.
23. World Health Organization. WHO Expert Committee on Diabetes Mellitus: Second Report. Geneva, Switzerland: World Health Organization; 1980. Technical Report Series, No. 646.
24. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1998;21(suppl 1):S0-S19.
25. Wahl PW, Psaty BM, Savage PJ, Orchard TJ, Robbins JA, Tracy RP. Diabetes in older adults: a comparison of the 1997 American Diabetes Association classification of diabetes mellitus with the 1985 WHO classification. Lancet. 1998;352:1012-1015.
26. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol. 1995;5: 278-285.
27. Breslow NE, Day NE. Statistical Methods in Cancer Research, Volume II: the Design and Analysis of Cohort Studies. Lyons, France: International Agency for Research on Cancer; 1987. WHO IARC Scientific Publication No. 82.
28. Klein R, Klein BEK, Moss SE, Linton KLP. The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Ophthalmology. 1992;99:58-62.
29. Temelkova-Kurktschiev TS, Koehler C, Leonhardt W, Schaper F, Henkel E, Siegert G, Hanefeld M. Increased intimal-medial thickness in newly detected type 2 diabetes. Diabetes Care. 1999;22:333-338.
30. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E, for the CARE investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events. Circulation. 1998;98:2513-2519.
31. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, for the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
32. Sacks FM, Preffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica W, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
33. Steiner G for the DAIS Project Group. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. Diabetologia. 1996;39:1655-1661.
34. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD, for the SENDCAP Study group. Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998;21:641-648.
35. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J, for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276: 1886-1982.
36. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
37. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt J, Fletcher AE, Forette F, Goldhaber A, Paatini P, Sarti C, Fagard R, for the Systolic Hypenension in Europe Trial Investigators. Effects of calcium-channel blackade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
38. Colwell JA. Aspirin therapy in diabetes. Diabetes Care. 1997;20: 1767-1771.
39. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE, for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet. 1999;353:611-616.
40. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet. 1999;353:617-622.
41. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
42. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
43. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS, and the Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VACSDM) group. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Intern Med. 1997;157: 181-188.